HUP0003949A2 - Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents
Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0003949A2 HUP0003949A2 HU0003949A HUP0003949A HUP0003949A2 HU P0003949 A2 HUP0003949 A2 HU P0003949A2 HU 0003949 A HU0003949 A HU 0003949A HU P0003949 A HUP0003949 A HU P0003949A HU P0003949 A2 HUP0003949 A2 HU P0003949A2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- vitronectin receptor
- pharmaceutical composition
- composition containing
- receptor antagonist
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 102100022337 Integrin alpha-V Human genes 0.000 title abstract 3
- 108010048673 Vitronectin Receptors Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 2
- 230000024279 bone resorption Effects 0.000 abstract 2
- -1 4-methyl-2-pyridyl Chemical group 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 210000002997 osteoclast Anatomy 0.000 abstract 1
- 230000001599 osteoclastic effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A találmány (I) képletű vegyületre, azaz (S)-4-(karboxi-metil)-8-{3-[(4-metil-2-piridil)-amino]-1-propoxi}-3-oxo-2-[4-(trifluor-metil)-benzil]-2,3,4,5-tetrahidro-1H-2-ben- zazepinre és gyógyászatilagelfogadható sóira vonatkozik. A találmány szerinti vegyület gátolja avitronektinnek és más RGD-tartalmú peptideknek a vitronektinreceptorhoz történő kötődését. Az osteoclastokon lévő vitronektinreceptor inhibíciója gátolja az osteoclasticus csontreszorpciót és ígyfelhasználható az olyan betegségek kezelésére, amelyekben acsontreszorpció egy patológiás állapottal, például osteoporosisszalvagy osteoarthritisszel áll összefüggésben. A találmány kiterjed avegyületek új intermediereire, valamint a vegyületeket tartalmazógyógyszerkészítményekre és a vegyületek gyógyászati alkalmazására is.. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5983297P | 1997-09-24 | 1997-09-24 | |
| PCT/US1998/019949 WO1999015170A1 (en) | 1997-09-24 | 1998-09-24 | Vitronectin receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0003949A2 true HUP0003949A2 (hu) | 2001-10-28 |
Family
ID=22025570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0003949A HUP0003949A2 (hu) | 1997-09-24 | 1998-09-24 | Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1017387A4 (hu) |
| JP (1) | JP2002528380A (hu) |
| KR (1) | KR20010024247A (hu) |
| CN (1) | CN1273529A (hu) |
| AU (1) | AU9577498A (hu) |
| BR (1) | BR9813208A (hu) |
| CA (1) | CA2303846A1 (hu) |
| HU (1) | HUP0003949A2 (hu) |
| IL (1) | IL135189A0 (hu) |
| NO (1) | NO20001514L (hu) |
| PL (1) | PL339413A1 (hu) |
| TR (1) | TR200000792T2 (hu) |
| WO (1) | WO1999015170A1 (hu) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000046215A1 (en) | 1999-02-03 | 2000-08-10 | Merck & Co., Inc. | Benzazepine derivatives as alpha-v integrin receptor antagonists |
| US6514964B1 (en) * | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| US20020072518A1 (en) * | 2000-08-29 | 2002-06-13 | Khanna Ish Kumar | Bicyclic alphavbeta3 antagonists |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| WO2002018340A1 (en) * | 2000-08-30 | 2002-03-07 | Pharmacia Corporation | GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS |
| DK1381384T3 (da) | 2001-04-24 | 2011-07-25 | Merck Patent Gmbh | Kombinationsterapi under anvendelse af anti-angiogene midler og TNFalfa |
| CN100560131C (zh) | 2001-10-22 | 2009-11-18 | 斯克里普斯研究学院 | 抗体靶向化合物 |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| US20090130098A1 (en) | 2006-01-18 | 2009-05-21 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
| CA2675813A1 (en) | 2007-01-18 | 2008-07-24 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Specific therapy and medicament using integrin ligands for treating cancer |
| AU2008321770B2 (en) | 2007-11-16 | 2012-09-06 | Ube Industries, Ltd. | Benzazepinone compound |
| WO2009111679A2 (en) * | 2008-03-06 | 2009-09-11 | Smithkline Beecham Corporation | Process |
| EP2395992A2 (en) | 2009-02-10 | 2011-12-21 | The Scripps Research Institute | Chemically programmed vaccination |
| KR20120003918A (ko) | 2009-03-30 | 2012-01-11 | 우베 고산 가부시키가이샤 | 눈 질환의 치료 또는 예방을 위한 의약 조성물 |
| JP5572996B2 (ja) * | 2009-05-15 | 2014-08-20 | 宇部興産株式会社 | ベンズアゼピノン化合物を有効成分として含有する医薬 |
| AU2010252280A1 (en) | 2009-05-25 | 2012-01-19 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
| CN103864765B (zh) * | 2014-03-05 | 2016-02-10 | 天津药物研究院 | 含有五元杂环的苯并氮杂卓类衍生物、其制备方法和用途 |
| WO2015181676A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10504807A (ja) * | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗剤 |
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
| JP2001501951A (ja) * | 1996-10-07 | 2001-02-13 | スミスクライン・ビーチャム・コーポレイション | 骨形成刺激方法 |
-
1998
- 1998-09-24 EP EP98949454A patent/EP1017387A4/en not_active Withdrawn
- 1998-09-24 CA CA002303846A patent/CA2303846A1/en not_active Abandoned
- 1998-09-24 AU AU95774/98A patent/AU9577498A/en not_active Abandoned
- 1998-09-24 KR KR1020007003088A patent/KR20010024247A/ko not_active Application Discontinuation
- 1998-09-24 PL PL98339413A patent/PL339413A1/xx unknown
- 1998-09-24 HU HU0003949A patent/HUP0003949A2/hu unknown
- 1998-09-24 WO PCT/US1998/019949 patent/WO1999015170A1/en not_active Application Discontinuation
- 1998-09-24 CN CN98809495A patent/CN1273529A/zh active Pending
- 1998-09-24 BR BR9813208-3A patent/BR9813208A/pt not_active Application Discontinuation
- 1998-09-24 TR TR2000/00792T patent/TR200000792T2/xx unknown
- 1998-09-24 IL IL13518998A patent/IL135189A0/xx unknown
- 1998-09-24 JP JP2000512539A patent/JP2002528380A/ja not_active Withdrawn
-
2000
- 2000-03-23 NO NO20001514A patent/NO20001514L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010024247A (ko) | 2001-03-26 |
| CN1273529A (zh) | 2000-11-15 |
| NO20001514D0 (no) | 2000-03-23 |
| EP1017387A4 (en) | 2004-08-18 |
| JP2002528380A (ja) | 2002-09-03 |
| BR9813208A (pt) | 2000-08-22 |
| CA2303846A1 (en) | 1999-04-01 |
| TR200000792T2 (tr) | 2000-09-21 |
| AU9577498A (en) | 1999-04-12 |
| NO20001514L (no) | 2000-03-23 |
| PL339413A1 (en) | 2000-12-18 |
| IL135189A0 (en) | 2001-05-20 |
| EP1017387A1 (en) | 2000-07-12 |
| WO1999015170A1 (en) | 1999-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0003949A2 (hu) | Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0003931A2 (hu) | Vitronektin receptor antagonisták, valamint a vegyületeket tartalmazó gyógyszerkészítmények | |
| LU91145I2 (fr) | FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX). | |
| BR9714358A (pt) | Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos | |
| MX9708840A (es) | Derivados de isoxazolina e isoxazol como antagonistas del receptor integrina. | |
| BG106251A (en) | Levodopa (carbidopa) entacapone pharmaceutical preparation | |
| DK0678026T3 (da) | Anvendelse af carbamazepin og oxcarbazepin ved fremstilling af lægemidler til behandling af Parkinsons sygdom og parkinsonisme-syndromer | |
| DE1073432T1 (de) | Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden | |
| PT1227806E (pt) | Formulacao farmaceutica contendo tolterodina e sua utilizacao | |
| JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
| IL115059A0 (en) | Novel pharmaceutical compositions for oral administration | |
| HUP0001527A2 (hu) | Laktózmentes, nem higroszkópos és vízmentes dekarboetoxiloratadin-tartalmú gyógyászati készítmények | |
| HUP0101411A2 (hu) | 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása | |
| IL119647A (en) | Crystalline modification v of the hydrochloride of (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman, its preparation and a pharmaceutical composition containing it | |
| AU6999796A (en) | Heterocyclic compounds as bradykinin antagonists | |
| FI972434A (fi) | Lamotrigiiniä sisältävä farmaseuttinen koostumus | |
| IL145645A0 (en) | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | |
| IL206566A0 (en) | Use of an antagonist to the igs4 neuromedin receptor polypeptide for the preparation of a medicament for the treatment of a disease related to the expression or acitivity of the igs4 neuromedin receptor polypeptide | |
| EP0952159A3 (en) | Use of somatostatin derivatives and/or of phenylhydrazone derivatives as antinflammatory or analgetic agents | |
| HUP0104804A2 (hu) | Tetrahidro-naftiridinil-származék, mint vitronektin receptor antagonista, eljárás előállítására és ezt tartalmazó gyógyszerkészítmény | |
| HUP9802897A2 (hu) | Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény | |
| BR0007686A (pt) | Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda | |
| DK0866711T3 (da) | Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö | |
| ATE180405T1 (de) | Arzneimittel enthaltend einen quisqualat-rezeptor-antagonisten und einen dopamin-agonisten zur behandlung des morbus parkinson | |
| ES476427A1 (es) | Procedimiento para preparar tetrahidro-1,3,5-triazina-2,6- dionas. |